Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Protein Domain Mimetics as In Vivo Modulators of Hypoxia-Inducible Factor Signaling

ABSTRACT: We performed gene expression profiling of hydrogen-bond surrogate that targets hypoxia-inducible transcription factior complex and results in inhibition of hypoxia-inducible genes with relatively minimal perturbation of non-targeted signaling pathways.

ORGANISM(S): Homo sapiens

PROVIDER: GSE48002 | GEO | 2013/06/18

SECONDARY ACCESSION(S): PRJNA208623

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Protein Domain Mimetics as In Vivo Modulators of Hypoxia-Inducible Factor Signaling

Project description:We performed gene expression profiling with oligonucleotide microarrays of hydrogen-bond surrogate targheting hypoxia-inducibletranscription factior complex, which resulted in an effective inhibition of hypoxia-inducible genes with relatively minimal perturbation of non-targeted signaling pathways. Hypoxic HeLa cells were treated with transcriptional inhibitors HBS 1, HBS 2 or vehicle and their expression profiles were compared to normoxic HeLa cells

2013-06-18 | E-GEOD-48002 | biostudies-arrayexpress

Designed Oligooxopiperazines as Modulators of Hypoxia-Inducible Factor Signaling

Project description:We performed gene expression profiling of oligooxopiperazines (OPs) targeting the hypoxia-inducible transcription factor complex. Treatment of cells with OPs inhibited hypoxia-inducible gene expression in A549 cells.

2013-06-30 | GSE48134 | GEO

Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling.

Project description:Selective blockade of gene expression by designed small molecules is a fundamental challenge at the interface of chemistry, biology, and medicine. Transcription factors have been among the most elusive targets in genetics and drug discovery, but the fields of chemical biology and genetics have evolved to a point where this task can be addressed. Herein we report the design, synthesis, and in vivo efficacy evaluation of a protein domain mimetic targeting the interaction of the p300/CBP coactivator with the transcription factor hypoxia-inducible factor-1α. Our results indicate that disrupting this interaction results in a rapid down-regulation of hypoxia-inducible genes critical for cancer progression. The observed effects were compound-specific and dose-dependent. Gene expression profiling with oligonucleotide microarrays revealed effective inhibition of hypoxia-inducible genes with relatively minimal perturbation of nontargeted signaling pathways. We observed remarkable efficacy of the compound HBS 1 in suppressing tumor growth in the fully established murine xenograft models of renal cell carcinoma of the clear cell type. Our results suggest that rationally designed synthetic mimics of protein subdomains that target the transcription factor-coactivator interfaces represent a unique approach for in vivo modulation of oncogenic signaling and arresting tumor growth.

| S-EPMC3785738 | biostudies-literature

Designed Oligooxopiperazines as Modulators of Hypoxia-Inducible Factor Signaling

Project description:We performed gene expression profiling for designed oligooxopiperazines targeting the hypoxia-inducible transcription factor complex, which resulted in an effective inhibition of hypoxia-inducible genes with relatively minimal perturbation of non-targeted signaling pathways. Hypoxic A549 cells were treated with transcriptional inhibitors BB2-162, BB2-125, BB2-282 or vehicle and their expression profiles were compared to normoxic A549 cells treated with vehicle.

2013-06-30 | E-GEOD-48134 | biostudies-arrayexpress

Hypoxia-inducible PRMT2 addiction in cancers

Project description:Hypoxia-inducible PRMT2 addiction in cancers

| PRJNA986065 | ENA

Attenuating Hypoxia Driven Malignant Behavior in Glioblastoma with a Novel Hypoxia-Inducible Factor 2 Alpha Inhibitor

Project description:Attenuating Hypoxia Driven Malignant Behavior in Glioblastoma with a Novel Hypoxia-Inducible Factor 2 Alpha Inhibitor

2020-09-10 | GSE147595 | GEO

Hypoxia-inducible PRMT2 addiction in cancers

Project description:Hypoxia-inducible transcription factors (HIFs) are crucial transcription factors for cellular response to low oxygen levels, but the key mediators for their downstream transcription activation are not well characterized. We previously found that PRMT2 activates target gene expression through its methyltransferase activity on histone H3R8. Here we find that PRMT2 expression is activated by HIF1 at hypoxic conditions. And PRMT2 activity is widely required for hypoxia-induced transcription activation. Accordingly, PRMT2 inactivation alleviates hypoxia-induced glioblastoma progression and chemotherapeutic resistance. And PRMT2 expression is associated with hypoxia signature

2024-04-01 | GSE235438 | GEO

Regulation of hypoxia-inducible factor activity by CHD4

Project description:Regulation of hypoxia-inducible factor activity by CHD4

| PRJNA530760 | ENA

Regulation of hypoxia-inducible factor activity by ZMYND8

Project description:Regulation of hypoxia-inducible factor activity by ZMYND8

| PRJNA428761 | ENA

Hypoxia-independent downregulation of hypoxia inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Project description:Hypoxia inducible factor 1 (HIF1) has been shown to cooperate with the androgen receptor (AR) in activation of oncogenic pathways in prostate cancer (PCa). Here we hypothesized that HIF1 also plays a role in PCa response to androgen deprivation therapy (ADT). Comparison of gene expression profiles of androgen exposed (AE) and androgen deprived (AD) CWR22 PCa xenografts identified 596 upregulated and 748 downregulated genes after ADT. Gene ontology (GO) analysis of the differentially expressed genes showed significant enrichment of the biological processes cell proliferation, cell cycle and metabolism and suggested suppression of these processes after ADT. A set of 80 hypoxia-inducible genes were identified in 22Rv1 and LNCaP cell lines treated with hypoxia and showed considerable overlap (53%) with the downregulated genes. Immunostaining of the hypoxia marker pimonidazole showed no difference between AE- and AD-tumors. Comparison of the differentially expressed genes with lists of 1115 direct AR- and 276 direct HIF1-target genes identified 138 AR- and 40 HIF1-targets that were regulated after ADT, including six shared AR- and HIF1-targets for which downregulation was confirmed with RT-PCR. Most HIF1-targets were downregulated and included in the significant biological processes and the set of hypoxia-inducible genes. The downregulation of HIF1-targets was consistent with decreased HIF1A immunostaining in AD- compared to AE-tumors (p=0.002). A decrease in HIF1A immunostaining after ADT was also demonstrated in a cohort of 35 PCa patients (p<0.001). These data suggest suppressed HIF1-signaling after ADT and a shared role of HIF1 and AR in the regressive phase of PCa after ADT. Prostate cancer xenografts were subjected to adrogen deprivation therapy and analysed with regard to changes in gene expressions. Cell culture experiments were performed to generate prostate cancer specific gene lists associated with hypoxia.

2013-10-02 | E-GEOD-42868 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data